
-
2007
Company Description
Kolltan Pharmaceuticals develops new-generation monoclonal antibody oncology therapeutics.
Kolltan Pharmaceuticals, Inc., is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
-
Manufacturer:
Science and Engineering -
Formed:
2007 -
Company Website:
-
Company E-mail:
-
Company Address:
300 George Street, Suite 530New Haven, CTUnited States -
CEO:
- Jane Pritchett Henderson
-
We recognize our sponsors starting at $1 per entry.
Learn more at https://www.ithistory.org/benefits